Drug × Cancer matrix

Drugs that target a gene either directly (oncogene) or via a synthetic-lethal partner (SLP) of a mutated tumour suppressor (TSG). Cell colour shows the strongest known status of that drug for that cancer subtype: approved clinical trial repositionable (potential reuse, no evidence yet) or blank.

Cancer key
GBM — Glioblastoma (CNS astrocytoma grade IV) LUAD — Lung adenocarcinoma SCLC — Small cell lung carcinoma LUSC — Lung squamous cell carcinoma OAC — Oesophageal adenocarcinoma OSCC — Oesophageal squamous cell carcinoma PDAC — Pancreatic ductal adenocarcinoma
Relationship
Show
Clear
Showing 200 of 416 drug-target rows in SSL view, for TSG = ERCC3.
Drug TSG SLP (drug target) GBM LUAD SCLC LUSC OAC OSCC PDAC #
olaparib ERCC3 PARP1 1
neo212 oral capsule, ipilimumab, pembrolizumab, nivolumab, regorafenib, carboplatin, paclitaxel, folfiri protocol, bevacizumab ERCC3 ABL1 3
regorafenib, (stivarga, bay73-4506), nivolumab (opdivo) ERCC3 ABL1 3
everolimus ERCC3 MTOR 6
regorafenib ERCC3 ABL1 6
7-hydroxystaurosporine, irinotecan hydrochloride, diagnostic laboratory biomarker analysis ERCC3 PDPK1 2
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib ERCC3 EPHB4 2
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib ERCC3 ABL1 2
alectinib, brigatinib, lorlatinib 100 mg, osimertinib, sotorasib, dabrafenib, trametinib, selpercatinib, pembrolizumab, cemiplimab, nivolumab, carboplatin, pemetrexed, paclitaxel ERCC3 ABL1 2
cixutumumab, everolimus, laboratory biomarker analysis, octreotide acetate, pharmacological study ERCC3 MTOR 2
dec-205/ny-eso-1 fusion protein cdx-1401, laboratory biomarker analysis, pharmacological study, sirolimus ERCC3 MTOR 2
entrectinib, entrectinib, alectinib, atezolizumab, ipatasertib, trastuzumab emtansine, idasanutlin, inavolisib, belvarafenib, pralsetinib, gdc-6036, camonsertib ERCC3 JAK2 2
ioa-244, avelumab injection, pemetrexed, cisplatin, ruxolitinib ERCC3 JAK2 2
regorafenib, laboratory biomarker analysis ERCC3 ABL1 2
temsirolimus ERCC3 MTOR 2
temsirolimus, laboratory biomarker analysis ERCC3 MTOR 2
bosutinib ERCC3 ABL1 6
entrectinib ERCC3 JAK2 6
ponatinib ERCC3 ABL1 6
ruxolitinib ERCC3 JAK2 6
tadalafil ERCC3 PDE5A 6
7-hydroxystaurosporine, fluorouracil ERCC3 PDPK1 1
7-hydroxystaurosporine, gemcitabine hydrochloride, pharmacological study, laboratory biomarker analysis ERCC3 PDPK1 1
aee788, everolimus ERCC3 MTOR 1
afatinib, dasatinib, palbociclib, everolimus, olaparib ERCC3 EPHB4 1
afatinib, dasatinib, palbociclib, everolimus, olaparib ERCC3 MTOR 1
afatinib, dasatinib, palbociclib, everolimus, olaparib ERCC3 ABL1 1
aldesleukin, antibody therapy, fluorouracil, gemcitabine hydrochloride, irinotecan hydrochloride, laboratory biomarker analysis, leucovorin calcium, oxaliplatin, paclitaxel albumin-stabilized nanoparticle formulation, sargramostim ERCC3 IL2RB 1
aldesleukin, autologous tumor cell vaccine, filgrastim, sargramostim, therapeutic autologous lymphocytes, carmustine, cisplatin, cyclophosphamide, paclitaxel, autologous bone marrow transplantation, conventional surgery, peripheral blood stem cell transplantation ERCC3 IL2RB 1
aldesleukin, autologous tumor cell vaccine, muromonab-cd3, sargramostim, therapeutic autologous lymphocytes, surgical procedure, radiation therapy ERCC3 IL2RB 1
aldesleukin, biopsy, biospecimen collection, computed tomography, cyclophosphamide, excisional biopsy, fludarabine, magnetic resonance imaging, standard treatment, therapeutic tumor infiltrating lymphocytes ERCC3 IL2RB 1
aldesleukin, muromonab-cd3, therapeutic tumor infiltrating lymphocytes, conventional surgery ERCC3 IL2RB 1
aldesleukin, therapeutic autologous lymphocytes, adjuvant therapy, conventional surgery ERCC3 IL2RB 1
aldesleukin, therapeutic autologous lymphocytes, zoledronic acid ERCC3 IL2RB 1
alendronate, etidronate, ibandronate, risedronate, raloxifene ERCC3 ESR2 1
alpelisib, everolimus, exemestane ERCC3 MTOR 1
apg101, alectinib, idasanutlin, atezolizumab, vismodegib, temsirolimus, palbociclib ERCC3 MTOR 1
au-007, aldesleukin, avelumab ERCC3 IL2RB 1
azacitidine, vorinostat, gemcitabine, busulfan, melphalan, dexamethasone, caphosol, glutamine, pyridoxine, rituximab ERCC3 DNMT1 1
azd6244, dacarbazine, erlotinib, docetaxel, temsirolimus ERCC3 MTOR 1
bethanechol ERCC3 CHRM5 1
bethanechol, gemcitabine, nab-paclitaxel ERCC3 CHRM5 1
bevacizumab, dasatinib, fluorouracil, leucovorin, leucovorin calcium, oxaliplatin, quality-of-life assessment ERCC3 EPHB4 1
bevacizumab, dasatinib, fluorouracil, leucovorin, leucovorin calcium, oxaliplatin, quality-of-life assessment ERCC3 ABL1 1
bevacizumab, dasatinib, placebo ERCC3 EPHB4 1
bevacizumab, dasatinib, placebo ERCC3 ABL1 1
bevacizumab, everolimus, octreotide acetate ERCC3 MTOR 1
bevacizumab, temsirolimus ERCC3 MTOR 1
botensilimab, balstilimab, chloroquine phosphate, celecoxib ERCC3 PDPK1 1
carboplatin, celecoxib, paclitaxel, adjuvant therapy, conventional surgery, neoadjuvant therapy ERCC3 PDPK1 1
celecoxib, cyclophosphamide, etoposide, thalidomide ERCC3 PDPK1 1
celecoxib, isotretinoin, temozolomide, thalidomide ERCC3 PDPK1 1
celecoxib, temozolomide, thalidomide, adjuvant therapy ERCC3 PDPK1 1
chemotherapy, cladribine, radiation therapy ERCC3 PNP 1
chemotherapy, suramin ERCC3 F2 1
chlorpromazine, temozolomide, radiation therapy ERCC3 ADRA1A 1
conventional surgery, laboratory biomarker analysis, sorafenib tosylate, temsirolimus ERCC3 MTOR 1
cpt- 11, cisplatin, celecoxib, radiation, surgery ERCC3 PDPK1 1
cyclophosphamide, fludarabine, aldesleukin, anti-hcd70 car transduced pbl ERCC3 IL2RB 1
cytoreductive surgery, perifosine, temsirolimus ERCC3 MTOR 1
dasatinib, erlotinib hydrochloride, gemcitabine hydrochloride ERCC3 EPHB4 1
dasatinib, erlotinib hydrochloride, gemcitabine hydrochloride ERCC3 ABL1 1
dasatinib, gemcitabine hydrochloride, laboratory biomarker analysis, mutation analysis, nucleic acid sequencing, immunohistochemistry staining method ERCC3 EPHB4 1
dasatinib, gemcitabine hydrochloride, laboratory biomarker analysis, mutation analysis, nucleic acid sequencing, immunohistochemistry staining method ERCC3 ABL1 1
dasatinib, laboratory biomarker analysis, physiologic testing ERCC3 EPHB4 1
dasatinib, laboratory biomarker analysis, physiologic testing ERCC3 ABL1 1
dasatinib, mfolfox6 ERCC3 EPHB4 1
dasatinib, mfolfox6 ERCC3 ABL1 1
dasatinib, pharmacological study ERCC3 EPHB4 1
dasatinib, pharmacological study ERCC3 ABL1 1
dasatinib, temozolomide, placebo, radiation therapy ERCC3 EPHB4 1
dasatinib, temozolomide, placebo, radiation therapy ERCC3 ABL1 1
decitabine, gemcitabine ERCC3 DNMT1 1
desflurane ERCC3 KCNA1 1
dexamethasone, ondansetron, quality-of-life assessment ERCC3 HTR4 1
dipyridamole, fluorouracil, leucovorin calcium, mitomycin c ERCC3 PDE10A 1
dipyridamole, fluorouracil, leucovorin calcium, mitomycin c ERCC3 PDE5A 1
disulfiram, copper, alkylating agents ERCC3 HSP90B1 1
disulfiram, copper, alkylating agents ERCC3 F2 1
disulfiram, copper, alkylating agents ERCC3 APOC3 1
disulfiram, copper, alkylating agents ERCC3 SERPIND1 1
durvalumab, gemcitabine, nab paclitaxel, tremelimumab, propranolol, cisplatin ERCC3 ADRB3 1
e. coli cd-expressing genetically modified neural stem cells, flucytosine, leucovorin calcium, pharmacological study, laboratory biomarker analysis ERCC3 DNMT1 1
e7 tcr cells, aldesleukin, fludarabine, cyclophosphamide ERCC3 IL2RB 1
epidermal growth factor receptor(egfrv)iii chimeric antigen receptor (car) transduced pbl, aldesleukin, fludarabine, cyclophosphamide ERCC3 IL2RB 1
eras-007, encorafenib, cetuximab, palbociclib ERCC3 STK36 1
eras-007, encorafenib, cetuximab, palbociclib ERCC3 MAPK9 1
erlotinib, temsirolimus, therapeutic conventional surgery, laboratory biomarker analysis, pharmacological study ERCC3 MTOR 1
everolimus, archival tissue analysis ERCC3 MTOR 1
everolimus, gefitinib ERCC3 MTOR 1
everolimus, placebo ERCC3 MTOR 1
everolimus, sorafenib ERCC3 MTOR 1
everolimus, temozolomide, microarray analysis, immunohistochemistry staining method ERCC3 MTOR 1
everolimus, temozolomide, radiation ERCC3 MTOR 1
everolimus, vatalanib, pharmacological study, laboratory biomarker analysis, dynamic contrast-enhanced magnetic resonance imaging, ultrasound imaging ERCC3 MTOR 1
flucytosine, polymerase chain reaction, immunohistochemistry staining method, gene therapy, pharmacological study, 3-tesla magnetic resonance imaging, laboratory biomarker analysis, therapeutic conventional surgery, e. coli cd-expressing genetically modified neural stem cells ERCC3 DNMT1 1
ft-2102, azacitidine, nivolumab, gemcitabine and cisplatin ERCC3 DNMT1 1
gemcitabine, oxaliplatin, imatinib ERCC3 ABL1 1
genistein, erlotinib hydrochloride, gemcitabine hydrochloride ERCC3 ESR2 1
imatinib, irinotecan, carboplatin ERCC3 ABL1 1
intestinal, multivisceral or modified multivisceral transplantation, alemtuzumab, tacrolimus, sirolimus ERCC3 MTOR 1
kras tcr-transduced pbl, aldesleukin, fludarabine, cyclophosphamide ERCC3 IL2RB 1
laboratory biomarker analysis, perifosine, temsirolimus, therapeutic conventional surgery ERCC3 MTOR 1
laboratory biomarker analysis, pharmacological study, temsirolimus, trebananib ERCC3 MTOR 1
lenalidomide, bevacizumab, sorafenib, temsirolimus, lenalidomide, oxaliplatin, leucovorin, 5-fluorouracil ERCC3 MTOR 1
lmb-100, tofacitinib, mesothelin expression ERCC3 JAK2 1
metformin xr, delayed metformin, sirolimus ERCC3 MTOR 1
nivolumab, tadalafil, oral vancomycin ERCC3 PDE5A 1
p-muc1c-allo1 car-t cells, rimiducid ERCC3 MTOR 1
pacritinib, sirolimus, tacrolimus, allogenic hematopoietic cell transplant (allohct) ERCC3 MTOR 1
pacritinib, sirolimus, tacrolimus, allogenic hematopoietic cell transplant (allohct) ERCC3 JAK2 1
pasireotide lar, everolimus, pasireotide lar and everolimus combination ERCC3 MTOR 1
pd0332991, anastrozole, goserelin, surgery (standard of care), tumor biopsy ERCC3 GNRHR 1
pegph20, nab-paclitaxel, gemcitabine, dexamethasone, enoxaparin ERCC3 F2 1
pembrolizumab, azacitidine ERCC3 DNMT1 1
pembrolizumab, tadalafil ERCC3 PDE5A 1
pentostatin, sirolimus, cyclophosphamide, allogeneic hematopoietic stem cell transplant (hsct), th2 rapa cells, donor lymphocyte harvest, induction therapy, gvhd prophylaxis, donor hematopoietic stem cell harvest ERCC3 MTOR 1
pep-3-klh conjugate vaccine, daclizumab, temozolomide, placebo, pep-3-klh ERCC3 IL2RB 1
pharmacological study, adjuvant therapy, 3-dimensional conformal radiation therapy, intensity-modulated radiation therapy, temsirolimus, temozolomide ERCC3 MTOR 1
proflavine ERCC3 F2 1
proflavine, mobile, augmented high resolution microendoscope ERCC3 F2 1
propranolol, placebo ERCC3 ADRB3 1
radiation therapy, temozolomide, bevacizumab, bevacizumab, everolimus ERCC3 MTOR 1
regorafenib, lomustine ERCC3 ABL1 1
regorafenib, temozolomide ERCC3 ABL1 1
ribociclib, everolimus ERCC3 MTOR 1
ridaforolimus, mk-0752, mk-2206 ERCC3 MTOR 1
rna-loaded dendritic cell vaccine, basiliximab ERCC3 IL2RB 1
romidepsin, azacitidine, nab-paclitaxel, gemcitabine, durvalumab, lenalidomide capsule ERCC3 DNMT1 1
ruxolitinib, erlotinib ERCC3 JAK2 1
ruxolitinib, radiation, temozolomide ERCC3 JAK2 1
ryz101, everolimus, sunitinib, octreotide, lanreotide ERCC3 MTOR 1
selinexor, temozolomide, generic radiation therapy (rt), selective serotonin receptor (5-ht3) antagonists, olanzapine, salt tablets, anti-diarrheal ERCC3 ADRA1A 1
sirolimus ERCC3 MTOR 1
sirolimus, placebo ERCC3 MTOR 1
sirolimus, vandetanib ERCC3 MTOR 1
sorafenib tosylate, erlotinib hydrochloride, tipifarnib, temsirolimus ERCC3 MTOR 1
sorafenib tosylate, everolimus, laboratory biomarker analysis, pharmacogenomic studies, pharmacological study ERCC3 MTOR 1
sorafenib, radiofrequency ablation (rfa) or surgery, everolimus, lanreotide ERCC3 MTOR 1
suramin, radiation therapy ERCC3 F2 1
sx-682, decitabine ERCC3 DNMT1 1
tacrolimus, methotrexate, sirolimus ERCC3 MTOR 1
tadalafil, gemcitabine, radiation, pancreaticoduodenectomy ERCC3 PDE5A 1
tadalafil, pembrolizumab, ipilimumab, crs-207 ERCC3 PDE5A 1
tamoxifen, etoposide ERCC3 ESR2 1
temozolomide, aprepitant, minocycline, disulfiram, celecoxib, sertraline, captopril, itraconazole, ritonavir, auranofin ERCC3 PDPK1 1
temozolomide, lomustine, regorafenib, radiation, paxalisib, val-083, vt1021, troriluzole, adi-peg 20 ERCC3 ABL1 1
temozolomide, temsirolimus ERCC3 MTOR 1
temsirolimus, bevacizumab ERCC3 MTOR 1
temsirolimus, docetaxel ERCC3 MTOR 1
temsirolimus, laboratory biomarker analysis, pharmacological study ERCC3 MTOR 1
temsirolimus, pegylated liposomal doxorubicin ERCC3 MTOR 1
temsirolimus, pharmacological study, cytokine levels ERCC3 MTOR 1
temsirolimus, pharmacological study, laboratory biomarker analysis ERCC3 MTOR 1
temsirolimus, vinorelbine ditartrate ERCC3 MTOR 1
tesevatinib ERCC3 EPHB4 1
tetrahydrouridine, decitabine ERCC3 DNMT1 1
therapeutic allogeneic lymphocytes, aldesleukin, laboratory biomarker analysis, positron emission tomography ERCC3 IL2RB 1
topotecan hydrochloride, 7-hydroxystaurosporine ERCC3 PDPK1 1
trametinib, ruxolitinib ERCC3 JAK2 1
trametinib, ruxolitinib, retifanlimab ERCC3 JAK2 1
unpulsed dcs, td, human cmv pp65-lamp mrna-pulsed autologous dcs, 111in-labeled dcs, temozolomide, saline, basiliximab ERCC3 IL2RB 1
vismodegib, sirolimus, positron emission tomography, computed tomography, pharmacological study, laboratory biomarker analysis, fludeoxyglucose f 18 ERCC3 MTOR 1
young til, aldesleukin, cyclophosphamide, fludarabine, pembrolizumab (keytruda) ERCC3 IL2RB 1
abarelix ERCC3 GNRHR 6
acetophenazine ERCC3 SIGMAR1 6
acetophenazine maleate ERCC3 SIGMAR1 6
acetylcholine ERCC3 CHRM5 6
acetylcholine chloride ERCC3 CHRM5 6
afatinib dimaleate ERCC3 EGFR 6
alfuzosin ERCC3 ADRA1A 6
alfuzosin hydrochloride ERCC3 ADRA1A 6
allylestrenol ERCC3 ESR2 6
amifampridine ERCC3 KCNA1 6
amifampridine phosphate ERCC3 KCNA1 6
amisulpride ERCC3 HTR4 6
antithrombin alfa ERCC3 F2 6
argatroban ERCC3 F2 6
azacitidine ERCC3 DNMT1 6
baricitinib ERCC3 JAK2 6
bazedoxifene ERCC3 ESR2 6
bazedoxifene acetate ERCC3 ESR2 6
bivalirudin ERCC3 F2 6
buserelin ERCC3 GNRHR 6
carbetapentane ERCC3 SIGMAR1 6
carbetapentane citrate ERCC3 SIGMAR1 6
carteolol ERCC3 ADRB3 6
carteolol hydrochloride ERCC3 ADRB3 6
carvedilol ERCC3 ADRB3 6
carvedilol ERCC3 ADRA1A 6
carvedilol phosphate ERCC3 ADRB3 6
carvedilol phosphate ERCC3 ADRA1A 6
cetrorelix acetate ERCC3 GNRHR 6
cetuximab ERCC3 EGFR 6
chlorotrianisene ERCC3 ESR2 6
cilastatin ERCC3 DPEP1 6
cilastatin sodium ERCC3 DPEP1 6
cisapride ERCC3 HTR4 6
clebopride ERCC3 HTR4 6
cyclofenil ERCC3 ESR2 6
Approval data manually curated from National Cancer Institute and Drugs@FDA. Clinical trials from ClinicalTrials.gov. Repositionable candidates from cansar.ai — these are potential drug-cancer reuse candidates, not evidence of efficacy.